^
Association details:
| Biomarker: | PD-L1 rs4143815 |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors
Published date:
05/18/2021
Excerpt:
To investigate the role of CTLA-4, PD-1 (programmed death-1), and PD-L1 (programmed death-ligand 1) single nucleotide polymorphisms (SNPs) in predicting clinical outcome of patients with advanced non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs)....PD-L1 rs4143815 SNP and the long clinical benefit group showed a statistically significant association (p = 0.02).
DOI:
10.1177/03008916211014954
